Clinical Trial Update: A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a quadrivalent HPV recombinant vaccine in Chinese healthy females was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts

Drugs mentioned

• Quadrivalent HPV recombinant vaccine (HPV vaccine)

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: Cervical Cancer, Genital Wart | Phase 3 | Status: TERMINATED